

Charity Registration Number 1121784

Company Registration Number 06249601 (England and Wales)

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

(COMPANY LIMITED BY GUARANTEE)

TRUSTEES' REPORT AND UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2025

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

CONTENTS

	Page
Legal and administrative information	1
Trustees' report	2 - 6
Statement of trustees' responsibilities	7
Independent Examiner's Report	8
Statement of financial activities	9
Balance sheet	10
Notes to the accounts	11-16

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	A Budgen K Hill K Stubbs R Hancock D Small
Secretary	A Budgen
Charity number	1121784
Company number	06249601
Principle address	Riverside East 2 Millsands Sheffield S3 8DT
Registered office	Riverside East 2 Millsands Sheffield S3 8DT
Accountants	Landin Wilcock & Co 68 Queen Street Sheffield S1 1WR
Bankers	CAF Bank 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4TA HSBC 22, The Moor Sheffield S1 4PA

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

TRUSTEES' REPORT

FOR THE YEAR ENDED 30 JUNE 2025

The trustees, who are also the directors of the charity for the purposes of the Companies Act, submit their annual report and the unaudited financial statements of the June Hancock Mesothelioma Research Fund for the year ended 30 June 2025. Reference and administrative information set out on page 1 form part of this report. The trustees confirm that these financial statements comply with current statutory requirements, in that they have complied with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Structure, governance and management

The June Hancock Mesothelioma Research Fund is a registered charity (charity number 1121784) and a company limited by guarantee (company number 06249601). The charity's only voting members are its charity trustees. It is currently managed by a committee of five who undertake all day to day tasks associated with running the charity and delivering its objectives. No paid staff are employed.

Governing documents

The charity was incorporated on 16th May 2007 and is governed by its Memorandum and Articles of Association. This report covers the accounting period for the year ended 30th June 2025.

Recruitment of trustees

The trustees meet regularly to discuss the charity's progress and formulate general policy. They are ultimately responsible for the day-to-day management of the charity, including the making, enforcing and altering of rules, and the authority for all expenditure. Trustees are elected and/or re-elected in accordance with the provisions set out in the organisation's constitution. The current operational management of the charity is conducted by the Trustees together with the help of several volunteers under the guidance of the trustees.

All decisions of a management nature are made by the board of trustees, the quorum is fifty percent.

The income and property of the charity shall be applied solely towards the promotion of its objects as set forth in the Memorandum of Association. No portion thereof shall be paid or transferred, directly or indirectly, by way of bonus or otherwise by way of profit, to members of the charity. No member of the board of trustees shall be appointed to any office of the charity paid by way of salary or fees. Neither shall they receive any remuneration or other benefit in money or kind from the charity.

The trustees, (who are also the directors for the purposes of company law), who served during the year were:

A Budgen
K Hill
K Stubbs
R Hancock
D Small

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

New trustees are appointed by a resolution of the existing trustees, and there is no requirement for trustees to retire annually and seek re-appointment. New trustees undertake an induction and training process that includes an interview with the existing trustees at which stage they are given a presentation of the charity's objectives and activities. They will also be provided with a bible of documents that includes strategy information, financial accounts, trustee minutes, publicity materials, key project information and Charity Commission information about the responsibilities of Charity Trustees.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

Risk assessment

The trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to these risks. The major risk to the charity is considered to be its reliance on donations and fund raising from the general public. A significant reduction in income would limit the development of the charity and the achievement of its objectives.

Objectives and activities

The primary object of the charity is to fund high quality research in pleural and peritoneal mesothelioma to improve treatment and care for people with mesothelioma. Our secondary objects include providing information and support to patients, their families and friends and to raise awareness of mesothelioma and the dangers of asbestos. Our volunteer-led model ensures that almost all the money raised through donations and fundraising is used to support researcher-led projects and post-graduate fellowships in the field of mesothelioma. We also use funds to support information and awareness about mesothelioma by maintaining a website and producing the JHMRF Mesothelioma Handbook, which is a free 96-page information booklet for newly diagnosed patients.

The main policies undertaken through the financial year in furtherance of these objectives were:

- Accepting donations from those wishing to raise money specifically for research into mesothelioma. People who have encountered the disease in themselves or loved ones can take comfort from the knowledge that the money raised will fund research to help sufferers of the disease now and in the future.
- Providing high quality, easy to understand and up to date information on mesothelioma in publications and on our website. This includes information about the disease itself, treatments, clinical trials, novel therapies, where to go for more help, and also details of regional asbestos support groups.
- Supporting events like Action Mesothelioma Day to provide information to patients and carers, promote a better understanding of mesothelioma and raise awareness of the health implications of asbestos and asbestos products.
- Inviting applications for high quality mesothelioma research projects in the UK. All applications are independently reviewed and assessed by a panel of experts.

Public benefit

We remain confident that we demonstrate properly the public benefit expected by the Charity Commission in the way that our objectives state above. The above objectives and activities are clearly of value to mesothelioma patients and their carers, family and friends.

The trustees confirm that they have complied with the requirements of Section 4 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Use of volunteers

There are no volunteers used in the daily duties of the charity, however, there are a number of academics and clinicians who volunteer to assist with the peer review process for new grant and fellowship applications, and interim and final reports submitted by existing grant holders.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

Grant award policy

The JHMRF runs a competitive award process when sufficient funds are available. Applications are invited in open, structured calls for high quality mesothelioma research projects. Health care professionals, post-doctoral scientists and other suitably qualified applicants are invited to apply for awards. Work must be carried out at a research institution in the UK. Research projects in basic science, translational research or applied health are considered but the primary focus must be mesothelioma.

The JHMRF funds major projects (up to £300,000), pump-priming grants (up to £25,000) and doctoral fellowships. A number of travel grants to attend scientific conferences or training courses are also available up to a maximum of £500. All applications received by the deadline are peer-reviewed by at least three independent expert referees, in accordance with AMRC guidelines. Our network of contacts provides a source of volunteer peer reviewers with specific medical and scientific expertise in a wide-range of areas. Applications and reviews are then scrutinised and prioritised by the JHMRF Scientific Advisory Group (SAG). The SAG comprises academics, research scientists and clinicians. It is currently chaired by a JHMRF trustee with research experience.

Research proposals are assessed against the following criteria:

- Quality of the research
- Importance of the research question(s)
- Relevance of the work to JHMRF research strategy
- Scientific potential of the research
- Originality of the research
- Ethicality and research governance of the research
- Sustainability of the research
- Management of the overall project

Additionally, fellowship applications are assessed for quality and suitability of the candidate, the host institution and the supervisor.

The review process generates a shortlist of prioritised applications, which is taken, to the JHMRF Board of Trustees. The Board makes the final decision on funding after consideration of the SAG's recommendations.

Funding calls are advertised on the websites of organisations such as RD Info, The British Lung Foundation and Mesothelioma UK and circulated to the mesothelioma research community via the distribution lists of special interest groups in the British Thoracic Oncology Group and the British Mesothelioma Interest Group.

Principal Sources of Funding

JHMRF's principal source of funding is generous donations, mainly from people affected by the disease. It has not engaged in any fundraising activities in the current year to 30 June 2025.

Achievements and performance

The JHMRF has continued to receive donations from supporters including legacies. As a result, the fund has slowly managed to rebuild its assets to replace the outlay in the last funding call. The JHMRF receives numerous enquiries about funding for research projects. One of the limitations of a volunteer-led model of operation and governance is that activity has to be planned around trustees' availability. Plans are underway to open a funding call in 2026 and the timing of the call will be notified in due course.

During the year 2024 to 2025, several projects awarded in the last funding round were completed or nearing completion. On Thursday 15 May 2025 the JHMRF held a Research Conference in Leeds to enable our awardees to share their findings with researchers across the UK. The conference was well attended with over 60 delegates registered including researchers, patients and members of the public and provided a great opportunity to explore new avenues for research.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

Achievements and performance continued

Presentations show-cased innovative approaches to the development of future treatments but also demonstrated some of the challenges of mesothelioma research:

Dr Astero Klampatsa and Dr Florencia Secchiari delivered a presentation highlighting the challenges of mesothelioma research. They explained how their original proposal for a pump-priming grant had to be repurposed from a study of precision cut tumour slices to a comprehensive proteomics analysis of mesothelioma, due to a lack of available samples.

Dr Kate Finegan updated on her feasibility study exploring a novel immunotherapy approach targeting ERK5 (an enzyme that plays a part in controlling how cells grow, divide and survive), to treat mesothelioma

Dr Matthew Wong presented on behalf of the PI: Dr Olivier Pardo to update on the major project award which aims to validate a novel therapeutic strategy and associated response biomarkers to replace current standard-of-care in mesothelioma treatment.

Dr Barbara Tanos and Ms Rebecca Collinson updated on progress with Ms Collinson's doctoral Fellowship project exploring the role of cilia in the development of malignant pleural mesothelioma.

There were also poster presentations on a variety of topics from researchers based in the Universities of Cambridge, Liverpool and Strathclyde.

JHMRF did not organise a standalone event on Action Mesothelioma Day 2025 but trustees attended meetings organised by other mesothelioma support groups in Sheffield and Portsmouth and delivered presentations aimed at raising awareness and promoting the fund.

The JHMRF continues to fulfil its commitment to building research capacity in mesothelioma by offering travel grants to support attendance at relevant training meetings and conferences. In late 2024 JHMRF awarded a travel grant to Dr Carsten Hansen from the University of Edinburgh, who was an invited speaker at the Federation of American Societies for Experimental Biology conference in Florida, USA in November 2024. Dr Hansen presented his work on the Hippo Pathway in Biology and Mesothelioma. This high-profile international conference also provided the opportunity to network with other researchers and discuss new developments in mesothelioma research.

Throughout the year, the JHMRF has continued to work with external partners in the UK and Europe, including Asbestos Victim Support Groups and Mesothelioma Patient Support Groups, the NIHR and NICE, the European Lung Foundation and the European Rare Disease Network. The JHMRF values these relationships to build a collaborative approach to mesothelioma research and drive improvements in treatment and care for patients.

Financial review

The Fund has continued to receive some extremely generous donations throughout the year. Donations come mainly from people affected by the disease.

The level and number of awards that will be offered in the future will necessarily be determined by the availability and sustainability of funding. Funds will be set aside to support annual applications for pilot and feasibility studies, and for travel and educational awards. The next call for a major project award will be announced in due course.

Reserves policy

The current level of reserves stands at £319,351. It is the policy of the charity to maintain unrestricted funds, which are the free reserves of the charity, the minimum level of reserves is £10,000. This provides sufficient funds to cover management, administration and support costs. Funds above this level will be available for the charity to support other projects in the future.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

Financial instruments

Objectives and policies

The Charity's activities expose it to a number of financial risks including credit risk and liquidity risk. The use of financial derivatives is governed by the charity's policies approved by the board of trustees, which provide written principles on the use of financial derivatives to manage these risks. The Charity does not use derivative financial instruments for speculative purposes.

Credit Risk

The Charity's principal financial assets are bank balances and cash, trade and other receivables, and investments.

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies.

The Charity has no significant credit risk.

Liquidity risk

In order to maintain liquidity to ensure that sufficient funds are available for ongoing operations and future developments, the Charity uses a mixture of long-term and short-term debt finance.

Further details regarding liquidity risk can be found in the statement of accounting policies in the financial statements.


Plans for the future

The charity will continue to pursue its main aim, which is to promote high quality research into mesothelioma in the UK. The JHMRF will work closely with the new Mesothelioma Research Network and other research partners to build collaborations and develop ideas that have potential to lead to real advances in research and care for mesothelioma. We will adopt a flexible approach to funding using small grants and training awards to support innovative areas of research and major project awards to progress ideas further.

The patient will remain at the heart of the JHMRF research strategy; mesothelioma is a disease with extremely poor outcomes and limited treatment options. Improving care for people with mesothelioma and increasing the range of therapeutic options available to them is a priority area for the fund. We aim to achieve this by building a strong and well-balanced portfolio of research, the outputs from which will be of real benefit to patients.

Mesothelioma is classed as an industrial disease and is caused by asbestos exposure. The JHMRF will work in partnership with other organisations like the HSE and the International Ban Asbestos Secretariat to raise awareness of asbestos in order to reduce the risk of people contracting mesothelioma in the future. The JHMRF will continue to support the call for a worldwide ban on the mining and manufacture of asbestos products, and recognises the need to seek more sustainable methods of providing employment and shelter for vulnerable populations in developing countries.

On behalf of the board of trustees



Adrian Budgen
Trustee
Dated: 20 March 2026



Dan Small
Trustee
Dated: 20 March 2026

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

STATEMENT OF TRUSTEES RESPONSIBILITIES

FOR THE YEAR ENDED 30 JUNE 2025

The trustees (who are also the directors of June Hancock Mesothelioma Research Fund for the purpose of company law) are responsible for preparing the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.


Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resource, including its income and expenditure, for the period.

In preparing these accounts, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the accounts comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the Charity on 20 March 2026 and signed on its behalf by:



Adrian Budgen
Trustee



Dan Small
Trustee

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

FOR THE YEAR ENDED 30 JUNE 2025

I report on the accounts of the Charity for the year ended 30 June 2025 which are set out on pages 9 to 16.

Your attention is to be drawn to the fact that the Charity has prepared the Financial Statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has since been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

Respective responsibilities of trustees and examiner

The trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the Charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

- (1) which gives me a reasonable cause to believe that in any material respect the requirements:
 - to keep accounting records in accordance with section 386 of the Companies Act 2006; and
 - to prepare accounts which accord with accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the statement of Recommended Practice: Accounting and Reporting by Charities have not been met; or
- (2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Tom Henshaw ACA
Landin Wilcock & Co
Chartered Accountants & Registered Auditors
68 Queen Street
Sheffield
S1 1WR

Dated: 23/03/2026

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 JUNE 2025

		Unrestricted funds	2025 Total	2024 Total
	Notes	£	£	£
<u>Income and Endowments from:</u>				
Income from investments	2	11,037	11,037	13,649
Income from donations and legacies	3	35,809	35,809	35,450
Total income and endowments		<u>46,846</u>	<u>46,846</u>	<u>49,099</u>
<u>Expenditure on:</u>				
Charitable activity	4	7,761	7,761	1,908
Research Grants & Costs	6	500	500	1,259
Net gains on investments	11	(2,099)	(2,099)	(5,028)
Total resources expended		<u>6,162</u>	<u>6,162</u>	<u>(1,861)</u>
Net income/(expenditure)		40,684	40,684	50,960
Transfers between funds	10	-	-	-
Net movement in funds		<u>40,684</u>	<u>40,684</u>	<u>50,960</u>
Total funds brought forward		278,667	278,667	227,707
Total funds carried forward	13	<u><u>319,351</u></u>	<u><u>319,351</u></u>	<u><u>278,667</u></u>

The results for the year derive from continuing activities and there were no income, resources expended or transfers with any Designated or Restricted Funds during the current or preceding financial period.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

UNAUDITED BALANCE SHEET

AS AT 30 JUNE 2025

		2025	2024
	Notes	£	£
Current assets			
Investments	11	190,615	183,164
Other debtors		1,065	1,105
Cash at bank and in hand		200,638	345,434
		<u>392,318</u>	<u>529,703</u>
Liabilities			
Creditors: amounts falling due within one year	12	1,380	1,260
Research Grants	6	71,587	178,189
		<u>(72,967)</u>	<u>(179,449)</u>
Total assets less current liabilities		319,351	350,254
Creditors due after more than one year: Research Grants	6	-	(71,587)
Net Assets		<u>319,351</u>	<u>278,667</u>
Income funds			
Unrestricted funds		319,351	278,667
Accumulated funds	13	<u>319,351</u>	<u>278,667</u>


The company is entitled to exemption from audit under Section 477 Companies Act 2006 for the year ended 30 June 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The accounts were approved by the board on 20 March 2026 and were signed by:



Adrian Budgen
Trustee



Dan Small
Trustee

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 30 JUNE 2025

1 Accounting policies

1.1 Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

1.2 Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Companies Act 2006 and the Charities Act 2011.

1.3 Basis of preparation

June Hancock Mesothelioma Research Fund meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The presentation and functional currency is considered to be pounds sterling because this is the currency in the primary economic environment in which the Charity operates.

1.4 Going concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

1.5 Summary of disclosure exemptions

The Charity has opted to adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

1.6 Fund accounting policy

Restricted funds are subject to specific conditions by donors as to how they may be used.

Unrestricted funds comprise funds that have been donated or generated through charitable activities which are not subject to any such usage conditions.

Designated funds are those either set aside by the trustees for specific purposes, or funds which are treated as such in order to follow accounting treatment guidelines as detailed within the Charities SORP (FRS 102) and the 2011 Charities Act.

Further details of each fund are disclosed in note 13.

1.7 Incoming and endowments

Donations, legacies and other forms of voluntary income are recognised as incoming resources when there is entitlement, certainty of receipt, except insofar as they are incapable of financial measurement.

Investment income

Investment income is recognised on a receivable basis.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

1.8 Resources expended

Resources expended are included in the Statement of Financial Activities on an accruals basis, inclusive of any VAT which cannot be recovered.

Expenditure which is directly attributable to charitable activities has been included in this cost category.

Governance costs are those incurred in the management and operation of the charity's projects and charitable activities, together with any compliance costs.

1.9 Taxation

The Charity is considered to pass the test set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

1.10 Cash and Cash Equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

1.11 Financial Instruments

Classification:

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Charity after deducting all of its liabilities.

Recognition and measurement:

All financial assets and liabilities are initially measured at fair value, except for those financial assets classified as at fair value through income or expenditure, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangements constitutes a financing transaction.

If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the Charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when

- a) the contractual rights to the cash flows from the financial asset expire or are settled,
- b) the Charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or
- c) the Charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

2 Investment income

	2025 £	2024 £
UK bank interest receivable	11,037	13,649

3 Incoming from donations and legacies

	2025 £	2024 £
Donations receivable	35,809	35,450

4 Charitable activity costs

	2025 £	2024 £
Fundraising and event expenditure	5,524	-
Governance costs	2,237	1,908
	7,761	1,908

5 Governance costs

	2025 £	2024 £
Accountancy & Professional fees	1,461	1,437
Bank charges	449	351
Miscellaneous expenses	327	120
	2,237	1,908

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

6 Research Grants

	2025 £	2024 £
Awarded in year:		
Projects and research fellowships	500	1,259
Charge in SOFA	500	1,259
Paid in the year	(178,689)	(267,170)
Movement	(178,189)	(265,911)
Balance at start of year	249,776	515,687
Balance at end of year	71,587	249,776
Due within one year	71,587	178,189
Due after more than one year	-	71,587
Balance at end of year	71,587	249,776

Grants awarded during the year:

JHMRF awarded a travel grant to Dr. Carsten Gram Hansen to present his mesothelioma research at the Hippo Pathway in Biology and Diseases conference in Melbourne, Florida, USA, in November 2024.

7 Trustees

No acting trustees (or any persons connected with them) received any remuneration during the year. No trustee travel expenses were reimbursed to Trustees during the year. (2024: £Nil).

8 Employees

Other than the trustees, the company had no employees.

9 Taxation

The Charity is a registered charity and is therefore exempt from taxation.

10 Transfers

There was no income or resources expended by way of any Designated or Restricted Funds, hence there were no transfers between funds during the period.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

11 Investments

	2025 £	2024 £
Quoted Investments & Long Term Deposits		
Balance at start of year	183,164	173,814
Additions in the year	5,352	4,321
Movement in valuation of investment	2,099	5,029
Balance at end of year	<u>190,615</u>	<u>183,164</u>

Investments includes an investment bond and two twelve month deposit accounts. At 30 June 2025 the market value of the bond was £66,340 and the amounts held on deposit total £124,275.

12 Creditors: amounts falling due within one year

	2025 £	2024 £
Accruals	<u>1,380</u>	<u>1,260</u>

13 Analysis of net assets between funds

	Unrestricted funds £	2025 Total £	2024 Total £
Fund balances at 30 June 2025 are represented by:			
Tangible fixed assets	-	-	-
Current assets	392,318	392,318	529,703
Creditors: amounts falling due within one year	(72,967)	(72,967)	(179,449)
Creditors: amounts falling due after more than one year	-	-	(71,587)
	<u>319,351</u>	<u>319,351</u>	<u>278,667</u>

14 Contingent liabilities

There were no contingent liabilities as at 30 June 2025.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

15 Capital commitments

There were no capital commitments as at 30 June 2025.

16 Post balance sheet events

There are no events after the balance sheet date which the trustees feel should be brought to the attention of the members.

17 Related Party Transactions

There have been no related party transactions in the reporting period that require disclosure.